Personal genetics-testing startup 23andMe has signed a deal with Genentech to find some new treatments for Parkinson's disease. The companies announced the deal on Tuesday.
As per the deal, Genentech will sequence the whole genomes of almost 3,000 people with Parkinson's disease in 23andMe's database. Later, the data will be used to find some new therapeutic targets that could treat the neurodegenerative condition.
Also read: Steve Wynn won't get a severance package